ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been given an average recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Austin D. Kim sold 590 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $29.96, for a total transaction of $17,676.40. Following the transaction, the executive vice president now owns 46,901 shares of the […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Austin D. Kim sold 590 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $29.96, for a total value of $17,676.40. Following the transaction, the executive vice president now owns 46,901 shares in the […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price hoisted by equities research analysts at Mizuho from $35.00 to $40.00 in a note issued to investors on Friday, MarketBeat.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 27.75% from the […]
Morgan Stanley upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from an equal weight rating to an overweight rating in a report released on Tuesday morning, Marketbeat Ratings reports. Morgan Stanley currently has $40.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $31.00. Several other analysts have also […]